Clinical Trial Update: Trial of Pembrolizumab in Cancer of Unknown Primary [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab in cancer of unknown primary site has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer of Unknown Primary Site

Drugs mentioned

• Keytruda (Pembrolizumab) (pembrolizumab)

Snippet

Sponsor: Imperial College London | Conditions: Cancer of Unknown Primary Site | Phase 2 | Status: COMPLETED